Comparison of the ability of different clinical treatment scores to estimate prognosis in high-risk early breast cancer patients: A hellenic cooperative oncology group study

PLoS ONE

Volumn 11, Issue 10, 2016, Pages

  Stavridi, Flora ^a   Kalogeras, Konstantine T ^b,c   Pliarchopoulou, Kyriaki ^d   Wirtz, Ralph M ^e   Alexopoulou, Zoi ^f   Zagouri, Flora ^g   Veltrup, Elke ^e   Timotheadou, Eleni ^b   Gogas, Helen ^g   Koutras, Angelos ^h   Lazaridis, Georgios ^b   Christodoulou, Christos ⁱ   Pentheroudakis, George ^j   Laskarakis, Apostolos ⁱ   Arapantoni Dadioti, Petroula ^k   Batistatou, Anna ^j   Sotiropoulou, Maria ^l   Aravantinos, Gerasimos ^m   Papakostas, Pavlos ^d   Kosmidis, Paris ^a   Pectasides, Dimitrios ^d   Fountzilas, George ^b   more..

^a HYGEIA HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Hellenic Cooperative Oncology Group   (Greece)

^d HIPPOKRATION HOSPITAL   (Greece)

^e STRATIFYER Molecular Pathology GmbH   (Germany)

^f Health Data Specialists Ltd   (Greece)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^h UNIVERSITY OF PATRAS   (Greece)

ⁱ METROPOLITAN HOSPITAL   (Greece)

^j UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^k Micromedica Histopathology Laboratory   (Greece)

^l ALEXANDRA HOSPITAL   (Greece)

^m AGII ANARGIRI CANCER HOSPITAL   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; KI 67 ANTIGEN; MESSENGER RNA; METHOTREXATE; PACLITAXEL; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ADJUVANT ONLINE SCORE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL TREATMENT SCORE; DISEASE FREE SURVIVAL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSTIC ASSESSMENT; RAC GTPASE ACTIVATING PROTEIN 1 GENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FOR RECURRENCE SCORE; TOPOISOMERASE II ALPHA GENE; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CANCER STAGING; COMPARATIVE STUDY; FEMALE; KAPLAN MEIER METHOD; MORTALITY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; ROC CURVE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84991218695     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0164013     Document Type: Article

References (52)

1. Arpino G, Generali D, Sapino A, Del Matro L, Frassoldati A, de Laurentis M, et al. Gene expression profiling in breast cancer: a clinical perspective. Breast. 2013; 22(2):109-20. Epub 2013/03/07. doi: 10.1016/j.breast.2013.01.016 PMID: 23462680.
2. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011; 378(9805):1812-23. Epub 2011/11/22. doi: 10.1016/S0140-6736(11) 61539-0 PMID: 22098854.
3. Sinn P, Aulmann S, Wirtz R, Schott S, Marme F, Varga Z, et al. Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility. Geburtshilfe und Frauenheilkunde. 2013; 73(9):932-40. Epub 2014/04/29. doi: 10.1055/s-0033-1350831 PMID: 24771945; PubMed Central PMCID: PMC3859151.
4. Toss A, Cristofanilli M. Molecular characterization and targeted therapeutic approaches in breast cancer. Breast cancer research: BCR. 2015; 17:60. Epub 2015/04/24. doi: 10.1186/s13058-015-0560-9 PMID: 25902832; PubMed Central PMCID: PMC4407294.
5. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nature reviews Cancer. 2007; 7(7):545-53. Epub 2007/06/23. doi: 10.1038/nrc2173 PMID: 17585334.
6. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet Oncology. 2010; 11(1):55-65. Epub 2009/12/17. doi: 10.1016/S1470-2045(09)70314-6 PMID: 20005174; PubMed Central PMCID: PMC3058239.
7. Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2014; 25(2):339-45. Epub 2013/12/19. doi: 10.1093/annonc/mdt494 PMID: 24347518.
8. Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(22):2783-90. Epub 2013/07/03. doi: 10.1200/JCO.2012.46.1558 PMID: 23816962.
9. Zhao X, Rodland EA, Sorlie T, Vollan HK, Russnes HG, Kristensen VN, et al. Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status. BMC cancer. 2014; 14:211. Epub 2014/03/22. doi: 10.1186/1471-2407-14-211 PMID: 24645668; PubMed Central PMCID: PMC4000128.
10. Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G. A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics. 2008; 24(19):2200-8. Epub 2008/07/19. doi: 10.1093/bioinformatics/btn374 PMID: 18635567; PubMed Central PMCID: PMC2553442.
11. Evers EE, Zondag GC, Malliri A, Price LS, ten Klooster JP, van der Kammen RA, et al. Rho family proteins in cell adhesion and cell migration. Eur J Cancer. 2000; 36(10):1269-74. Epub 2000/07/07. doi: 10.1016/s0959-8049(00)00091-5 PMID: 10882865.
12. Tang Y, Olufemi L, Wang MT, Nie D. Role of Rho GTPases in breast cancer. Frontiers in bioscience: a journal and virtual library. 2008; 13:759-76. Epub 2007/11/06. doi: 10.2741/2718 PMID: 17981586.
13. Welsh CF. Rho GTPases as key transducers of proliferative signals in g1 cell cycle regulation. Breast cancer research and treatment. 2004; 84(1):33-42. Epub 2004/03/05. doi: 10.1023/B:BREA. 0000018425.31633.07 PMID: 14999152.
14. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. British journal of cancer. 2002; 87(6):635-44. Epub 2002/09/19. doi: 10.1038/sj.bjc.6600510 PMID: 12237774; PubMed Central PMCID: PMC2364248.
15. Pliarchopoulou K, Kalogeras KT, Kronenwett R, Wirtz RM, Eleftheraki AG, Batistatou A, et al. Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Cancer chemotherapy and pharmacology. 2013; 71(1):245-55. Epub 2012/10/26. doi: 10.1007/s00280-012-2002-z PMID: 23096218.
16. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2005; 16(11):1723-39. Epub 2005/06/28. doi: 10.1093/annonc/mdi352 PMID: 15980158.
17. Fountzilas G, Christodoulou C, Bobos M, Kotoula V, Eleftheraki AG, Xanthakis I, et al. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. Journal of translational medicine. 2012; 10:212. Epub 2012/10/25. doi: 10.1186/1479-5876-10-212 PMID: 23092535; PubMed Central PMCID: PMC3499161.
18. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2011; 22(8):1736-47. Epub 2011/06/29. doi: 10.1093/annonc/mdr304 PMID: 21709140; PubMed Central PMCID: PMC3144634.
19. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2001; 19(4):980-91. Epub 2001/02/22. PMID: 11181660.
20. Campbell HE, Taylor MA, Harris AL, Gray AM. An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. British journal of cancer. 2009; 101(7):1074-84. Epub 2009/09/03. doi: 10.1038/sj.bjc.6605283 PMID: 19724274; PubMed Central PMCID: PMC2768087.
21. Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, Rutgers SM, et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. The Lancet Oncology. 2009; 10(11):1070-6. Epub 2009/10/06. doi: 10.1016/S1470-2045(09)70254-2 PMID: 19801202.
22. Bhoo-Pathy N, Yip CH, Hartman M, Saxena N, Taib NA, Ho GF, et al. Adjuvant! Online is overoptimistic in predicting survival of Asian breast cancer patients. Eur J Cancer. 2012; 48(7):982-9. Epub 2012/03/01. doi: 10.1016/j.ejca.2012.01.034 PMID: 22366561.
23. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(12):2716-25. Epub 2005/04/20. doi: 10.1200/JCO.2005.06.178 PMID: 15837986.
24. van Kleef JJ, Bretveld R, Groothuis-Oudshoorn K, van der Palen J, Jobsen JJ, Struikmans H, et al. Population-based validation study of Adjuvant! for primary breast cancer patients in the Netherlands. San Antonio Breast Cancer Symposium; 2015; San Antonio, TX, USA.
25. Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, et al. Postoperative dosedense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2005; 16(11):1762-71. Epub 2005/09/09. doi: 10.1093/annonc/mdi366 PMID: 16148021.
26. Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, et al. Postoperative dosedense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2008; 19(5):853-60. Epub 2007/11/29. doi: 10.1093/annonc/mdm539 PMID: 18042835.
27. Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M, et al. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast cancer research and treatment. 2012; 132(2):609-19. Epub 2011/12/22. doi: 10.1007/s10549-011-1913-4 PMID: 22187126.
28. Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast cancer research and treatment. 2011; 128(2):447-56. Epub 2011/05/20. doi: 10.1007/s10549-011-1572-5 PMID: 21594665.
29. Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, et al. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. PLOS ONE. 2012; 7(6):e37946. Epub 2012/06/09. doi: 10.1371/journal.pone. 0037946 PMID: 22679488; PubMed Central PMCID: PMC3367950.
30. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast cancer research and treatment. 2006; 100 (2):229-35. Epub 2006/08/26. doi: 10.1007/s10549-006-9242-8 PMID: 16932852.
31. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature medicine. 1998; 4(7):844-7. Epub 1998/07/14. doi: 10.1038/nm0798-844 PMID: 9662379.
32. Skacel M, Skilton B, Pettay JD, Tubbs RR. Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data. Applied immunohistochemistry & molecular morphology: AIMM/official publication of the Society for Applied Immunohistochemistry. 2002; 10(1):1-6. Epub 2002/03/15. doi: 10.1097/00129039-200203000-00001 PMID: 11893029.
33. Fountzilas G, Kourea HP, Bobos M, Televantou D, Kotoula V, Papadimitriou C, et al. Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer research. 2011; 31(9):3007-18. Epub 2011/08/27. PMID: 21868552.
34. Psyrri A, Kalogeras KT, Kronenwett R, Wirtz RM, Batistatou A, Bournakis E, et al. Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2012; 23(6):1422-7. Epub 2011/11/08. doi: 10.1093/annonc/mdr527 PMID: 22056852.
35. Fountzilas G, Dafni U, Bobos M, Kotoula V, Batistatou A, Xanthakis I, et al. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. BMC cancer. 2013; 13:163. Epub 2013/03/30. doi: 10.1186/1471-2407-13-163 PMID: 23537287; PubMed Central PMCID: PMC3621498.
36. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(1):118-45. Epub 2006/12/13. doi: 10.1200/JCO. 2006.09.2775 PMID: 17159189.
37. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(16):2784-95. Epub 2010/04/21. doi: 10.1200/JCO.2009.25.6529 PMID: 20404251; PubMed Central PMCID: PMC2881855.
38. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute. 2009; 101 (10):736-50. Epub 2009/05/14. doi: 10.1093/jnci/djp082 PMID: 19436038; PubMed Central PMCID: PMC2684553.
39. Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). The Lancet Oncology. 2010; 11(3):266-74. Epub 2010/01/19. doi: 10.1016/S1470-2045(10)70006-1 PMID: 20079691.
40. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(7):859-67. Epub 2010/12/30. doi: 10.1200/JCO.2009.27.5644 PMID: 21189395; PubMed Central PMCID: PMC3068060.
41. Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens MR, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26(30):4869-74. Epub 2008/09/17. doi: 10.1200/JCO.2007.13.4296 PMID: 18794552.
42. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(8):1323-33. Epub 2009/02/11. doi: 10.1200/JCO.2007.14.8197 PMID: 19204209.
43. Pentheroudakis G, Kotoula V, Eleftheraki AG, Tsolaki E, Wirtz RM, Kalogeras KT, et al. Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG). PLOS ONE. 2013; 8(7):e70634. Epub 2013/08/08. doi: 10.1371/journal.pone.0070634 PMID: 23923010; PubMed Central PMCID: PMC3726626.
44. Pentheroudakis G, Raptou G, Kotoula V, Wirtz RM, Vrettou E, Karavasilis V, et al. Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial. PLOS ONE. 2015; 10(5):e0124612. Epub 2015/05/15. doi: 10.1371/journal.pone.0124612 PMID: 25970543; PubMed Central PMCID: PMC4430485.
45. Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2001; 19 (4):972-9. Epub 2001/02/22. PMID: 11181659.
46. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29 (32):4273-8. Epub 2011/10/13. doi: 10.1200/JCO.2010.31.2835 PMID: 21990413.
47. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000; 56(2):337-44. Epub 2000/07/06. doi: 10.1111/j.0006-341x.2000. 00337.x PMID: 10877287.
48. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics. 2005; 61 (1):92-105. Epub 2005/03/02. doi: 10.1111/j.0006-341X.2005.030814.x PMID: 15737082.
49. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359(9324):2131-9. Epub 2002/07/02. doi: 10.1016/s0140-6736(02)09088-8 PMID: 12090977.
50. Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015; 33(8):916-22. Epub 2014/10/22. doi: 10.1200/JCO.2014.55.6894 PMID: 25332252.
51. Jankowitz RC, Cooper K, Erlander MG, Ma XJ, Kesty NC, Li H, et al. Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer. Breast cancer research: BCR. 2011; 13(5):R98. Epub 2011/10/18. doi: 10.1186/bcr3038 PMID: 21999244; PubMed Central PMCID: PMC3262211.
52. Hearne BJ, Teare MD, Butt M, Donaldson L. Comparison of Nottingham Prognostic Index and Adjuvant Online prognostic tools in young women with breast cancer: review of a single-institution experience. BMJ open. 2015; 5(1):e005576. Epub 2015/01/30. doi: 10.1136/bmjopen-2014-005576 PMID: 25628047; PubMed Central PMCID: PMC4316437.